Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 11,433 matching trials from the live ClinicalTrials.gov search.
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Quemliclustat, Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Biopsy Procedure
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Alzheimer Disease
Interventions
Investigational drug
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
34
States / cities
Peoria, Arizona • Beverly Hills, California • Los Alamitos, California + 29 more
Completed Phase 1Phase 2 Interventional Results available

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

NCT03008187
Conditions
Acute Myeloid Leukemia
Interventions
MEN1703
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Atlanta, Georgia • Cleveland, Ohio • Portland, Oregon + 4 more
Conditions
LAM, Lymphangioleiomyomatosis
Interventions
Sirolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 5 more
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
Conditions
Tumors Characterized by Genetic Abnormalities of ALK
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Conditions
Bipolar Disorder
Interventions
lamictal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
46
States / cities
Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more
Conditions
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Neoplasm, Midgut Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Refractory Digestive System Neuroendocrine Neoplasm
Interventions
Abemaciclib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Colorectal Cancer
Interventions
Automated Mailing, Automated Mailing Plus Assisted, Auto Plus Assisted Plus Navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 73 Years
Enrollment
4,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Puberty, Precocious
Interventions
Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Conditions
Prostate Cancer
Interventions
ZD4054, Palcebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 35 more
Conditions
Lymphoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 9 more
Active, not recruiting Not applicable Interventional Results available

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

NCT02000115
Conditions
Aortic Valve Stenosis
Interventions
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 56 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Ivonescimab Injection, Pembrolizumab Injection
Biological
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
Conditions
Insomnia Disorder
Interventions
Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Anniston, Alabama • Birmingham, Alabama • Little Rock, Arkansas + 33 more
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Plaque Removal of a Novel Brushing Device

NCT05038293
Conditions
Dental Plaque
Interventions
Automated mouthpiece-based toothbrush, Manual toothbrush
Device
Lead sponsor
University of Washington
Other
Eligibility
5 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
2,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
211
States / cities
Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
21 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Denver, Colorado • Ann Arbor, Michigan • Dallas, Texas + 1 more
Conditions
Major Depressive Disorder
Interventions
GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more